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Abstract
Objectives
To assess the impact of sources of drug information on antibiotic prescribing patterns (quan-
tity and quality) among primary care physicians.
Methods
We conducted a cohort study on primary care physicians who were actively engaged in
medical practice in 2010 in a region in north-west Spain (Galicia), fulfilling inclusion criteria
(n = 2100). As the independent variable, we took the perceived utility of 6 sources of infor-
mation on antibiotics, as measured by the validated KAAR-11 questionnaire. As dependent
variables, we used: (1) a quality indicator (appropriate quality, defined as any case where 6
of the 12 indicators proposed by the European Surveillance of Antimicrobial Consumption
Network [ESAC-Net] were better than the mean values for Spain); and, (2) a quantity indica-
tor (high prescribing), defined as any case where defined daily doses (DDD) per 1 000
inhabitants per day of antibacterials for systemic use were higher than the mean values for
Spain. The adjusted odds ratio for a change in the interquartile range (IqOR) for each
sources of information on antibiotics was calculated using Generalized Linear Mixed
Models.
Results
The questionnaire response rate was 68%. Greater perceived utility of pharmaceutical sales
representatives increases the risk of having high prescribing (1/IqOR = 2.50 [95%CI: 1.63–
3.66]) and reduces the probability of having appropriate quality (1/IqOR = 2.28 [95%CI:
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1.77–3.01]). Greater perceived utility of clinical guidelines increases the probability of having
appropriate quality (1/IqOR = 1.25 [95%CI: 1.02–1.54]) and reduces the probability of high
prescribing (1/IqOR = 1.25 [95%CI: 1.02–1.54]).
Conclusions
Sources of information on antibiotics are an important determinant of the quantity and qual-
ity of antibiotic prescribing in primary care. Commercial sources of information influence pre-
scribing negatively, and clinical guidelines are associated with better indicators.
Introduction
Misuse of antibiotics is the principal cause of the problem of resistance. [1,2] Notwithstanding
the strategies developed to improve prescribing [3,4] antibiotic use continues to grow. [5]
Around 90% of all antibiotic prescriptions are issued in primary care, [6–8] where an apprecia-
ble gap has been observed between clinical guidelines and practice. [9] The factors that affect
misprescribing in community settings are both numerous and inter-related, [10,11] and pre-
dominant among them are the sources of information through which physicians acquire
information.
The sources of information used by physicians have been described as one of the main
determinants of drug prescribing quality, [12–15] and there is evidence to show the important
role played by the pharmaceutical industry: indeed, exposure to pharmaceutical company
information has been seen to be associated with higher prescribing, higher costs and lower pre-
scribing quality. [13–15]
However, there are few studies that specifically evaluate the influence of the sources of
information used by physicians on antibiotic prescribing, [15–19] despite the fact that, in such
a case, any misprescription, in addition to raising the risk of adverse events and healthcare
costs, would also increase the development of resistance. [20]
Accordingly, this paper sought to evaluate the influence of the perceived utility of drug
information sources, on drug quality and quantity. To this end, we used the KAAR-11 ques-
tionnaire, [21] which was developed by our team on the basis of focal group studies, [22] and
has already been used in previous studies [23,24] to identify attitudes and knowledge associ-
ated with misprescription of antibiotics.
Methods
Study setting
Our study was conducted in Galicia. Galicia is a region in north-west Spain with a population
of 2.7 million, 24.3% of whom are over 65 years of age. Population density is 91,4 habitants/m2
and decreases as one moves inland from the coast, so distances to a public health centre tend
to increase. [25] Practically all the population is covered by the Spanish National Health Sys-
tem (NHS). The NHS is almost fully funded by taxes and provision of all health services, other
than pharmaceuticals, is free of charge at the point of delivery. Prior to 2012, the NHS afforded
universal coverage, and pharmaceutical services were co-financed by outpatients, with pen-
sioners and their beneficiaries being exempt from co-payment, and non-pensioners and their
beneficiaries paying 40% of the retail price. Medication may only be dispensed by community
or hospital pharmacies, and for some types of medication, e.g., antibiotics, a physician’s
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prescription is compulsory; even so, the dispensing of drugs without a prescription continues
to exist in Spain. [26,27] In Galicia, outpatient care is organised in two systems, namely:
healthcare or primary care centres, where medical care is given by appointment and each phy-
sician is assigned a fixed population quota; and 24-hour emergency outpatient centres, where
there are no population quotas assigned to each physician, but emergency care is instead given
on demand to whatever proportion of the population that requires it.
In Spain, relations between the pharmaceutical industry and the healthcare system are par-
tially regulated by domestic legislation; [28,29] legislative gaps are covered by the industry, and
self-regulation predominates in the form of a Good Practice Code. [30] However, the degree of
compliance with these rules and regulations is not optimal. [31–33]
Study design and population
A cohort study covering all primary care physicians working for the NHS in Galicia in 2010
(N = 3675) was carried out. From those the following were excluded: physicians exclusively
assigned to emergency services; medical residents in training; and temporary staff. [23] Physi-
cians exclusively assigned to emergency services were excluded, since they do not have a desig-
nated number of listed patients, thus rendering it impossible to calculate DID (Defined daily
dose -DDD- per 1000 Inhabitants per Day) indicators that require the number of patients
attended as their denominator.
Measure
All physicians who fulfilled the inclusion criteria were sent a letter describing the study, a ques-
tionnaire on antibiotic prescribing, a prepaid self-addressed envelope for returning the com-
pleted questionnaire, as well as a small gift (ballpoint pen or pencil). In cases where there was
no response to the questionnaire, this was re-sent a maximum of 4 times.
The validated KAAR-11 (Knowledge and Attitudes regarding Antibiotics and Resistance)
questionnaire was used: further details about the development and validation of the KAAR-11
questionnaire can be found elsewhere. [21] This questionnaire evaluates: (i) the perceived util-
ity of sources of information (clinical practice guidelines, documentation from the pharmaceu-
tical industry, pharmaceutical industry training (courses, sessions, congresses . . . organized
specifically by the pharmaceutical industry), medical representatives (or pharmaceutical sales
representatives), previous clinical experience and other specialist) in the management of upper
respiratory tract infections; (ii) healthcare criteria which may influence prescribing (number
of patients, time devoted to each patient, and whether or not physicians work on-call duty
shifts); and (iii) knowledge and attitudes regarding antibiotics and resistance. The results were
assessed using a continuous, horizontal, visual analogue scale (VAS), scored in a range from 0
(total disagreement) to 10 (total agreement).
Follow-up and outcome measures
The NHS provided monthly online prescription records for physicians from January 2008 to
December 2010. Drug-indication information was, however, unavailable.
To assess the quantity and quality of antibiotic prescriptions (dependent variables) we cal-
culated the 12 indicators proposed by the European Surveillance of Antimicrobial Consump-
tion (ESAC), [34] validated by Coenen et al, [35] which we then used to construct the
dichotomous dependent variables, namely, the quantity and quality of prescriptions. In the
case of the quantity of prescriptions we used indicator J01_DID (consumption of antibacterials
for systemic use expressed in defined daily doses/1000 inhabitants/day). Appropriate prescrib-
ing quantity (lower quantity) was assumed to exist in any case where the value of this indicator
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was better than the reference value for Spain. [23] Prescribing quality was deemed to be appro-
priate (Appropriate Quality Prescription of Antibiotics: AQPA) in any case where half (6/12)
or more of the annual ESAC indicators for each physician were better than the reference values
for Spain (see Apendix 1). We have selected these cut-points to avoid their opportunistic selec-
tion. [23,24] Moreover, we considered the characteristics of the primary care centers that
could act as potentially confusing covariates, in addition to the care criteria that were collected
in the KAAR-11 questionnaire: rural/urban primary care center; interior/coast primary care
center; availability of extra-hospital emergency services; center with/without residency train-
ing; center with specialties; and distance from the primary care center to the nearest hospital.
Statistical analysis
Generalized linear mixed models were applied to statistical analysis. To construct the models,
we used the quantity (J01_DID ESAC indicator) and the quality of prescription (AQPA) as
dependents variables, with individual observations (per year and physician) as level 1 and phy-
sicians as level 2; random effects were considered among physicians using R (R Foundation for
Statistical Computing). In view of the fact that the response variables were dichotomous, these
models were fitted with the binomial family, using the lme4 package for the R free software
environment for statistical computing. [36] To construct the models, we first performed a
bivariate analysis, and then selected all exposure and potential confounding variables having a
P-value lower than 0.2. Second, the variables so selected were then studied in a multivariate
analysis. The variables with the highest level of statistical significance were successively elimi-
nated, provided that the coefficients of the principal variables of exposure changed by no more
than 10% and improved the Schwartz’s Bayesian Information Criterion, [37] until the most
appropriate model had been obtained.
To take into account the scale of independent variables and their distribution among the
study subjects, we calculated the interquartile odds ratio (Iq OR), which is based on an incre-
mental exposure corresponding to the interquartile range on the scale of the perceived utility
of the source of information measures. [38] To express the results, we applied the following
three-step procedure:
i. firstly, we calculated the odds ratios (ORs) with their 95% confidence intervals for the con-
tinuous variable, which indicates the increase/decrease in the probability of having appro-
priate prescribing quantity or quality for an increase of 1 unit on the continuous VAS (scale
range 0–10) that measured the perceived utility of sources of information;
ii. secondly, we calculated the Iq OR, by multiplying the IQR (Interquartile Range) by the
OR; and,
iii. thirdly, in any case where the OR was lower than 1, we calculated the inverse of the Iq OR
(1/Iq OR), which can be interpreted as the increase in the probability of having appropriate
prescribing quantity or quality when scale values decrease from the 75th to the 25th
percentile.
Ethics and confidentiality
The study was approved by the Galician Ethics Committee (code number 2007/107). The phy-
sicians included in the study were informed through a letter, as described in the section mea-
sures. The physicians accepted to participate in the study if they answered the questionnaire.
To ensure confidentiality, once the data needed to obtain the prescription indicators had been
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linked to the results of the questionnaires, they were furnished by the Galician NHS in an
anonymised format such that no indicator could be related to a specific professional.
Results
A total of 2100 (57.1%) physicians fulfilled the inclusion criteria, with a 68% (n = 1428)
response rate to the postal questionnaire. The indicator values for responders and non-
responders were very similar. [23] In terms of quantity, 21.2% of responders registered better
prescription values (indicator J01_DID) than the Spanish mean, and 66.1% registered AQPA.
Table 1 shows that a higher degree of the management of upper respiratory tract infections
deriving from information sources from pharmaceutical companies was associated with a
higher probability of prescribing more antibiotics, namely, 1/IqOR = 2.50 (95%CI: 1.63–3.66,
p<0.001) for pharmaceutical sales representatives and 2.09 (95%CI: 1.70–2.87, p<0.001) for
pharmaceutical documentation. In contrast, the management of upper respiratory tract infec-
tions deriving from clinical guidelines was associated with a lower probability of antibiotic pre-
scribing: IqOR = 1.25; 95%CI: 1.02–1.54, p = 0.031).
Table 2 shows that a higher degree of the management of upper respiratory tract infections
deriving from sources of information from the pharmaceutical industry was associated with
worse prescribing quality, namely, 1/IqOR = 2.28 (95%CI: 1.77–3.01, p<0.001) for pharma-
ceutical sales representatives, 2.28 (95%CI: 1.70–3.01, p<0.001) for pharmaceutical industry
courses, and 2.09 (95%CI: 1.63–2.74, p<0.001) for pharmaceutical documentation. A higher
degree of management of upper respiratory tract infections deriving from clinical guidelines
was associated with better quality but with effect magnitudes lower than those deriving from
commercial guidelines: IqOR = 1.25 (95%CI: 1.02–1.54, p = 0.026).
Discussion
The results of this large-sized cohort study show that sources of information on antibiotics are
an important determinant of the quantity and quality of antibiotic prescribing in primary care.
Whereas commercial sources of information influence prescribing negatively, clinical guide-
lines are the sole resource associated with better indicators, albeit with lower effect
magnitudes.
The considerable influence exerted by the pharmaceutical industry on antibiotic mispre-
scribing (with effect magnitudes of more than twofold) is a reflection of the important role
Table 1. Association between information sources and antibiotic prescribing in terms of quantity (OR of a physician registering values better than the Spanish ref-
erence for ESAC indicator J01_DID,a on comparing the 25th to the 75th percentile of each source of information).
Percentile Quantity
Source of informationb 25 50 75 Iq OR (95% CI) Inverse Iq OR (95% CI) p value
Clinical Practice Guidelines 7.5 9 9.5 1.25 (1.02–1.54) — 0.031
Documentation of Pharmaceutical Industry 2 4 5.5 — 2.09 (1.70–2.87) <0.001
Pharmaceutical Industry Training 2.5 5 6 — 1.45 (0.93–1.15) 0.188
Medical Representatives 1.5 3 5 — 2.50 (1.63–3.66) <0.001
Previous clinical experience 7 8 9.5 — 1.27 (0.77–2.12) 0.348
Other specialists 7 8.5 9.5 — 1.03 (0.93–1.23) 0.888
Abbreviations. Iq OR: interquartile odds ratio; CI: confidence interval; DID: DDDs (assumed average maintenance dose per day for a drug used for its main indication
in adults) per 1000 inhabitants per day.
a J01_DID: consumption of antibacterials for systemic use expressed in DID.
b Measured using a continuous, horizontal, visual analogue scale. Recorded answers were scored in a range from zero (total disagreement) to ten (total agreement).
https://doi.org/10.1371/journal.pone.0221326.t001
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that it plays in antibiotic prescribing. These results are consistent, both with research results
on the effect of pharmaceutical company information on global prescribing habits, and with
the volume of resources that the industry allocates to the promotion of medications. [19, 39]
Despite the pharmaceutical sector’s proposals for self-regulation and the reduction in the
number of pharmaceutical sales representatives after the 2010 economic crisis, the majority of
primary care physicians regularly receive pharmaceutical sales representatives and accept their
gifts. [40] Moreover, regulations governing the relations between the industry and the health-
care system are frequently infringed. [41] Influence on prescribers is based on psychological
mechanisms that determine clinical decision-making. Physicians display contradictions in
their relationship with the industry, justifying it and considering that it does not affect them
on an individual basis, while at the same time regarding it as affecting their colleagues. [42]
According to some authors, they develop strategies to resolve cognitive dissonance, which
entail conserving a self-image of independence and credibility without dispensing with their
omnipresent interactions with the industry. [43]
The high effect magnitude encountered by us could also be due to the fact that antibiotics
are a group of medical drugs with specific characteristics which can be used for their promo-
tion and could favour their over/misprescribed: (1) promotion based on effectiveness rather
than appropriateness; (2) favouring the short-term view of the individual patient to the detri-
ment of a longer-term population-based stance; and/or, (3) advocating prescribing in the face
of diagnostic uncertainty and/or fear of the consequences of not prescribing. [23] The per-
ceived utility of clinical guidelines is the only resource associated with better prescribing, albeit
with a much lower magnitude (IqOR = 1.25) than that of commercial sources, which indicates
that these would seem to have less influence. This finding is consistent with the underuse of
guidelines [44,45] and the gap between evidence-based recommendations and clinical reality.
[46–48] Even though there is evidence to show that clinical guidelines could be biased due to
authors’ conflicts of interest with pharmaceutical companies, [49] this fact is probably less wor-
rying in the case of antibiotics. Something that also has to be borne in mind is that public con-
cern about antimicrobial resistance tends to favour greater control of rational antibiotic use,
which is reflected in more independent guidelines. [50–52]
Table 2. Association between information sources and antibiotic prescribing in terms of quality (OR of a physi-
cian showing Appropriate Quality Prescription of Antibiotics,a on comparing the 25th to the 75th percentile of each
source of information).
Quality
Source of informationb Iq OR (95% CI) Inverse Iq OR (95% CI) p value
Clinical Practice Guidelines 1.25 (1.02–1.54) — 0.026
Documentation of Pharmaceutical Industry — 2.09 (1.63–2.74) <0.001
Pharmaceutical Industry Training — 2.28 (1.70–3.01) <0.001
Medical Representatives — 2.28 (1.77–3.01) <0.001
Previous clinical experience — 2.35 (1.80–3.05) <0.001
Other specialists — 1.23 (1.00–1.55) 0.057
Abbreviations. Iq OR: interquartile odds ratio; CI: confidence interval; DID: DDDs (assumed average maintenance
dose per day for a drug used for its main indication in adults) per 1000 inhabitants per day.
a Appropriate quality prescription of antibiotics (AQPA): half or more ESAC indicator values better than the
reference values for Spain.
b Measured using a continuous, horizontal, visual analogue scale. Recorded answers were scored in a range from zero
(total disagreement) to ten (total agreement).
https://doi.org/10.1371/journal.pone.0221326.t002
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Our study has a series of strengths, the chief of which is the use of the first fully-validated
questionnaire, [21] which ensures that our findings are based, not on simulations, but on real
physician-based prescription data. [53] Furthermore, the use of ESAC indicators [35] guaran-
tees the absence of opportunism in the choice of the most favourable indicators. In addition,
the use of these indicators favours the comparability of results at European level.
Some limitations must also be considered. Firstly, there could be a tendency on the part of
physicians to answer in way that they perceive as being more socially acceptable (social desir-
ability bias). [54] However, this would affect the absolute scores but not the calculation of effect
measures (IqOR). Secondly, while a possible non-response bias might exist, it has to be said
that, not only was the response rate (68%) higher than that obtained in studies with postal
questionnaires, [55] but there were hardly any differences between responders and non-
responders. [23] Thirdly, even though data on indications were not available to us, we never-
theless feel that, due the large size of the number of registered patients per physician (median
1329) and the analysis being adjusted for potential confounding factors, differences in quality
and quantity indicators among physicians cannot be attributed to variations in patient mor-
bidity. Fourth, It is possible that there may be differences in the patient mix in a specific pri-
mary care practice (e.g., more elderly patients, lower or higher area served) but we feel that
such differences should not be very great, given the large size of physicians’quotas (n>1000)
and the fact that most of the indicators are ratios or proportions relative to the size of the popu-
lation attended (DHD, District Health Department) or, ratios or proportions whereby the
indicators are automatically adjusted. Should there be differences between physicians’ quotas
which might affect outcomes (quantity and quality of prescriptions), we feel that this would
not be associated -positively or negatively- with the perceived utility of physicians’ sources of
information. This could cause a non-differential misclassification in the outcome (indicators),
which would lead to an underestimate of the effect (and in turn towards the null hypothesis).
[56] If, despite this potential underestimate, physicians’ commercial sources of information
show an effect, it can be assumed that the effect would be greater still.
In view of the fact that there are local circumstances (organisation of the healthcare system,
legislation of relations with the industry, physicians antibiotic culture, etc.) which can affect
the results obtained and determine the applicability of our results to different healthcare sys-
tems, we feel that generalizability should be approached with caution, though there are numer-
ous studies which have described the pharmaceutical industry ‘s influence on the healthcare
system [57] and drug prescribing. [58–62] Moreover, it is possible that in medical circles that
are less regulated than Spain’s (e.g., some developing countries), the influence exerted by infor-
mation provided by the industry on prescribing patterns could be even greater. [62,63].
In conclusion, improving antibiotic prescribing is a complex task that calls for multiple
complementary approaches. Reducing the gaps between scientific evidence and clinical prac-
tice is one of the challenges that must be overcome to achieve this goal. Our results seem to
support the need to reduce the effect of the industry and foster the use of more independent
resources, such the adequate implementation of independent clinical guidelines, in order to
rationalise antibiotic prescribing.
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